DK3458083T3 - Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf - Google Patents
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf Download PDFInfo
- Publication number
- DK3458083T3 DK3458083T3 DK17726458.7T DK17726458T DK3458083T3 DK 3458083 T3 DK3458083 T3 DK 3458083T3 DK 17726458 T DK17726458 T DK 17726458T DK 3458083 T3 DK3458083 T3 DK 3458083T3
- Authority
- DK
- Denmark
- Prior art keywords
- polynucleotides encoding
- encoding interleukin
- interleukin
- polynucleotides
- encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338483P | 2016-05-18 | 2016-05-18 | |
US201762443693P | 2017-01-07 | 2017-01-07 | |
PCT/US2017/033422 WO2017201350A1 (en) | 2016-05-18 | 2017-05-18 | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3458083T3 true DK3458083T3 (da) | 2023-01-30 |
Family
ID=58794205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17726458.7T DK3458083T3 (da) | 2016-05-18 | 2017-05-18 | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
Country Status (22)
Country | Link |
---|---|
US (5) | US10646549B2 (da) |
EP (2) | EP3458083B1 (da) |
JP (2) | JP7246930B2 (da) |
KR (2) | KR20220159479A (da) |
CN (1) | CN109195621A (da) |
AU (1) | AU2017268397B2 (da) |
CA (1) | CA3024470A1 (da) |
DK (1) | DK3458083T3 (da) |
ES (1) | ES2941411T3 (da) |
FI (1) | FI3458083T3 (da) |
HR (1) | HRP20230050T1 (da) |
HU (1) | HUE061077T2 (da) |
IL (1) | IL262501A (da) |
LT (1) | LT3458083T (da) |
MX (2) | MX2018013509A (da) |
PL (1) | PL3458083T3 (da) |
PT (1) | PT3458083T (da) |
RS (1) | RS63912B1 (da) |
RU (1) | RU2769316C2 (da) |
SG (1) | SG11201809381XA (da) |
SI (1) | SI3458083T1 (da) |
WO (1) | WO2017201350A1 (da) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CN105980401A (zh) | 2013-10-03 | 2016-09-28 | 现代治疗公司 | 编码低密度脂蛋白受体的多核苷酸 |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
EP4036079A3 (en) | 2015-12-22 | 2022-09-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
LT3458083T (lt) | 2016-05-18 | 2023-02-10 | Modernatx, Inc. | Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3551193A4 (en) * | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
EP3596041B1 (en) | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
EP3801562A4 (en) * | 2018-05-31 | 2022-06-29 | Beth Israel Deaconess Medical Center | Rna-aided immunotherapeutics |
US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
GB2606038B (en) | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
AU2019338535A1 (en) * | 2018-09-14 | 2021-04-15 | Modernatx, Inc. | Methods and compositions for treating cancer using mRNA therapeutics |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
WO2020146700A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
KR20210113655A (ko) | 2019-01-10 | 2021-09-16 | 얀센 바이오테크 인코포레이티드 | 전립선 신생항원 및 이의 용도 |
MX2021010995A (es) * | 2019-03-14 | 2021-12-10 | Engene Inc | Recubrimiento reversible de nanopartículas de quitosano-ácido nucleico y métodos para su uso. |
US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
CN109932511B (zh) * | 2019-03-22 | 2020-02-04 | 南昌大学第二附属医院 | 用于肝癌筛查的尿液外泌体磷脂标志物及其试剂盒 |
US20200325241A1 (en) * | 2019-04-11 | 2020-10-15 | Massachusetts Institute Of Technology | Novel chimeric antigen receptors and libraries |
SG11202112922WA (en) | 2019-05-22 | 2021-12-30 | Massachusetts Inst Technology | Circular rna compositions and methods |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
CA3168509A1 (en) * | 2020-02-19 | 2021-08-26 | Elias SAYOUR | Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
CN115297868B (zh) * | 2020-02-21 | 2024-04-12 | 联合治疗公司 | 用于编码核糖核酸的器官保护性表达和调节的组合物及方法 |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
KR20220166802A (ko) | 2020-04-09 | 2022-12-19 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 나노입자 조성물 |
CN116648510A (zh) | 2020-05-17 | 2023-08-25 | 贝林格尔.英格海姆国际有限公司 | 用于受调控基因治疗的病毒载体和核酸 |
US20230295257A1 (en) | 2020-07-24 | 2023-09-21 | Strand Therapeutics Inc. | Lipid nanoparticle comprising modified nucleotides |
US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
AU2022205679A1 (en) | 2021-01-08 | 2023-07-06 | Strand Therapeutics Inc. | Expression constructs and uses thereof |
US11524023B2 (en) * | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
AU2022268465A1 (en) * | 2021-05-06 | 2023-03-09 | Stemirna Therapeutics Co., Ltd. | A lipid |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
CN116829578A (zh) * | 2021-10-08 | 2023-09-29 | 苏州艾博生物科技有限公司 | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 |
EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
CN116179549A (zh) | 2021-12-08 | 2023-05-30 | 南京吉迈生物技术有限公司 | 通过5’utr序列变体修饰基因转录和翻译效率 |
CN114957027B (zh) * | 2022-01-13 | 2023-05-19 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023196988A1 (en) * | 2022-04-07 | 2023-10-12 | Modernatx, Inc. | Methods of use of mrnas encoding il-12 |
CN116535491B (zh) * | 2022-05-06 | 2024-03-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
CN114994331B (zh) * | 2022-05-17 | 2023-02-24 | 无锡科金生物科技有限公司 | 一种检测蛋白表达水平的试剂盒及其制备方法和应用 |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024020453A2 (en) * | 2022-07-20 | 2024-01-25 | Hdt Bio Corp. | Immune system modulators and uses thereof |
DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
US6140496A (en) | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
CA2268276A1 (en) | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Gene expression and delivery systems and uses |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
CA2309535A1 (en) | 1997-11-12 | 1999-05-20 | Brigham And Women's Hospital, Inc. | The translation enhancer element of the human amyloid precursor protein gene |
CA2641217A1 (en) | 1997-11-20 | 1999-06-03 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
KR100519895B1 (ko) | 1998-04-23 | 2005-10-13 | 다카라 바이오 가부시키가이샤 | Dna 의 합성방법 |
AU761520B2 (en) | 1998-09-15 | 2003-06-05 | Genetics Institute, Llc | Treatment of Kaposi's Sarcoma with IL-12 |
WO2000018778A1 (en) | 1998-09-29 | 2000-04-06 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
AU4050801A (en) | 2000-01-20 | 2001-07-31 | Unitectra Inc. | Intra-tumoral administration of il-12 encoding nucleic acid molecules |
AU3120601A (en) | 2000-01-28 | 2001-08-07 | Scripps Research Inst | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
ES2164011B1 (es) | 2000-02-25 | 2003-05-16 | Inst Cientifico Tecnol Navarra | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. |
EP1268759B1 (en) | 2000-03-15 | 2006-09-27 | Genexine Co., Ltd. | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
KR20020010206A (ko) | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신 |
EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
WO2003004685A2 (en) | 2001-07-03 | 2003-01-16 | University Of Utah Research Foundation | Soluble steroidal peptides for nucleic acid delivery |
EP2390329B1 (en) | 2001-09-28 | 2018-04-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
ATE427992T1 (de) | 2001-11-14 | 2009-04-15 | Toyo Boseki | Dna-synthesepromotoren, mit dna-polymerase assoziierte faktoren und nutzung davon |
CA2409775C (en) | 2001-12-03 | 2010-07-13 | F. Hoffmann-La Roche Ag | Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro |
AU2003228440B2 (en) | 2002-04-01 | 2008-10-02 | Walter Reed Army Institute Of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
US7595303B1 (en) | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
CA3031833C (en) | 2003-05-30 | 2022-07-26 | University Of South Florida | Uses of il-2 as a therapeutic medicament in combination with electroporation for the treatment of malignancies |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
EP1640018A1 (en) | 2004-09-24 | 2006-03-29 | Universität Zürich | Combinational therapy for treating cancer |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US7550264B2 (en) | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
KR20080025181A (ko) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법 |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
JP5225087B2 (ja) | 2005-08-24 | 2013-07-03 | ザ スクリプス リサーチ インスティチュート | 翻訳エンハンサーエレメント依存性のベクター系 |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
EA015338B1 (ru) | 2005-12-30 | 2011-06-30 | Мерк Патент Гмбх | ВАРИАНТЫ ИЛ-12p40 С УЛУЧШЕННОЙ СТАБИЛЬНОСТЬЮ |
EP2586455B1 (en) | 2006-01-05 | 2014-06-25 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP2487252B1 (en) | 2006-01-05 | 2014-10-15 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon cancer |
WO2007084364A2 (en) | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Improved il-12 for expression in mammalian cells |
KR101241477B1 (ko) | 2006-01-27 | 2013-03-08 | 엘지이노텍 주식회사 | 질화물 반도체 발광소자 및 그 제조 방법 |
EP2522746B1 (en) | 2006-03-02 | 2014-11-12 | The Ohio State University Research Foundation | MicroRNA expression profile associated with pancreatic cancer |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
ES2425416T3 (es) | 2006-11-01 | 2013-10-15 | The Ohio State University Research Foundation | Firma de expresión del microARN para predecir la supervivencia y la metástasis en el carcinoma hepatocelular |
US20090092974A1 (en) | 2006-12-08 | 2009-04-09 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
EP2207891B1 (en) | 2006-12-22 | 2012-07-25 | Archemix LLC | Materials and methods for the generation of transcripts comprising modified nucleotides |
US8765462B2 (en) | 2007-05-04 | 2014-07-01 | University Health Network | IL-12 immunotherapy for cancer |
WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
TWI359030B (en) | 2007-08-24 | 2012-03-01 | Univ Nat Taiwan | Treatment of cellular proliferative disorders |
ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
US20110086904A1 (en) | 2007-09-17 | 2011-04-14 | The Trustees Of The University Of Pennsylvania | GENERATION OF HYPERSTABLE mRNAs |
EP2399610A3 (en) * | 2007-09-24 | 2012-09-05 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
RU2524431C2 (ru) | 2007-09-26 | 2014-07-27 | Интрексон Корпорейшн | Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии |
AU2008329755A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | MicroRNA expression profiling and targeting in peripheral blood in lung cancer |
SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
CN102015027A (zh) | 2008-02-28 | 2011-04-13 | 俄亥俄州立大学研究基金会 | 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途 |
EP2279254B1 (en) * | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
WO2009140206A1 (en) | 2008-05-11 | 2009-11-19 | The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services | Improved expression of il-12 family heterodimers |
US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
CN102439169B (zh) | 2008-11-13 | 2014-11-19 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
PT4209510T (pt) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t |
EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
US20120264626A1 (en) | 2009-05-08 | 2012-10-18 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof |
ES2901627T3 (es) | 2009-06-10 | 2022-03-23 | Arbutus Biopharma Corp | Formulación lipídica mejorada |
ES2587963T3 (es) | 2009-07-31 | 2016-10-27 | Ethris Gmbh | ARN con una combinación de nucleótidos no modificados y modificados para la expresión de proteínas |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
ME03091B (me) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
WO2012009644A2 (en) | 2010-07-16 | 2012-01-19 | Arizona Board Of Regents | Methods to identify synthetic and natural rna elements that enhance protein translation |
WO2012038448A1 (en) | 2010-09-21 | 2012-03-29 | Riboxx Gmbh | Method for synthesizing rna using dna template |
WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
KR20120066952A (ko) | 2010-12-15 | 2012-06-25 | 주식회사 롤팩 | 7층 구조의 공압출 항균 진공포장 필름 및 그 제조방법 |
EP2651445A2 (en) | 2010-12-16 | 2013-10-23 | SPRNA GmbH | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
CA2831613A1 (en) * | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20140113978A1 (en) | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
EP2706690B1 (en) | 2011-05-02 | 2018-03-21 | LG Electronics Inc. | Method for transmitting/receiving data in wireless access system and base station for same |
EP2944961A1 (en) | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
DK2732052T3 (da) | 2011-07-15 | 2017-02-20 | Leo Pharma As | Diagnostisk mikroRNA-profilering ved kutant T-cellelymfom (CTCL) |
US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
EP4015005A1 (en) | 2011-10-03 | 2022-06-22 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20150017121A1 (en) | 2011-10-11 | 2015-01-15 | Universitat Zurich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
JP6333730B2 (ja) | 2011-12-12 | 2018-05-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
EP2672197A1 (de) | 2012-06-06 | 2013-12-11 | Hörmann Energietechnik GmbH & Co. KG | Montageanordnung zur dachseitigen Montage von Flächenkörpern an einem Bauwerk |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
US20140020675A1 (en) | 2012-07-18 | 2014-01-23 | Chandrashekhar Sonwane | Solar receiver |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
CN102876684B (zh) * | 2012-09-17 | 2014-10-08 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
PT2922554T (pt) * | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
EP2929035A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
JP6352950B2 (ja) | 2013-03-08 | 2018-07-04 | ノバルティス アーゲー | 活性薬物の送達のための脂質と脂質組成物 |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
CN105142676B (zh) | 2013-03-14 | 2022-06-28 | 夏尔人类遗传性治疗公司 | Cftr mrna组合物以及相关方法和用途 |
AU2014239250A1 (en) | 2013-03-14 | 2015-08-27 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger RNA |
MX2015011945A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ, インコーポレイテッド | mRNAによってコードされる抗体を送達するための方法及び組成物 |
MX2015011943A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. |
EP2970940B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
HUE039189T2 (hu) | 2013-03-15 | 2018-12-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
WO2015024667A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Method for increasing expression of rna-encoded proteins |
PL3044234T3 (pl) | 2013-09-13 | 2020-10-19 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środków terapeutycznych i diagnostycznych |
JP6558699B2 (ja) | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン |
AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
ES2865699T3 (es) | 2013-10-22 | 2021-10-15 | Translate Bio Inc | Formulaciones de lípidos para la administración de ARN mensajero |
WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
US20150190506A1 (en) * | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US20160311879A1 (en) * | 2013-12-18 | 2016-10-27 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptides, and uses thereof |
CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
AU2014375402B2 (en) | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
RS63848B1 (sr) * | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
EP3326641B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
US10682401B2 (en) | 2015-05-19 | 2020-06-16 | Morphogenesis, Inc. | Multi-indication mRNA cancer immunotherapy |
US9636388B2 (en) | 2015-05-19 | 2017-05-02 | Morphogenesis, Inc. | Multi-indication mRNA cancer immunotherapy |
CA2998810A1 (en) * | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3205356A1 (en) | 2016-02-10 | 2017-08-16 | Onkoloski Institut Ljubljana | Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof |
EP3211000B1 (en) | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
LT3458083T (lt) | 2016-05-18 | 2023-02-10 | Modernatx, Inc. | Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
JP2019532648A (ja) | 2016-10-07 | 2019-11-14 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | がんの治療のための膜係留il−12を発現しているt細胞 |
-
2017
- 2017-05-18 LT LTEPPCT/US2017/033422T patent/LT3458083T/lt unknown
- 2017-05-18 EP EP17726458.7A patent/EP3458083B1/en not_active Revoked
- 2017-05-18 KR KR1020227040214A patent/KR20220159479A/ko not_active Application Discontinuation
- 2017-05-18 AU AU2017268397A patent/AU2017268397B2/en active Active
- 2017-05-18 FI FIEP17726458.7T patent/FI3458083T3/fi active
- 2017-05-18 CA CA3024470A patent/CA3024470A1/en active Pending
- 2017-05-18 ES ES17726458T patent/ES2941411T3/es active Active
- 2017-05-18 PL PL17726458.7T patent/PL3458083T3/pl unknown
- 2017-05-18 RS RS20230055A patent/RS63912B1/sr unknown
- 2017-05-18 RU RU2018144292A patent/RU2769316C2/ru active
- 2017-05-18 DK DK17726458.7T patent/DK3458083T3/da active
- 2017-05-18 PT PT177264587T patent/PT3458083T/pt unknown
- 2017-05-18 HU HUE17726458A patent/HUE061077T2/hu unknown
- 2017-05-18 KR KR1020187036222A patent/KR102469450B1/ko active IP Right Grant
- 2017-05-18 WO PCT/US2017/033422 patent/WO2017201350A1/en unknown
- 2017-05-18 JP JP2018560509A patent/JP7246930B2/ja active Active
- 2017-05-18 SI SI201731299T patent/SI3458083T1/sl unknown
- 2017-05-18 MX MX2018013509A patent/MX2018013509A/es unknown
- 2017-05-18 CN CN201780030730.8A patent/CN109195621A/zh active Pending
- 2017-05-18 HR HRP20230050TT patent/HRP20230050T1/hr unknown
- 2017-05-18 SG SG11201809381XA patent/SG11201809381XA/en unknown
- 2017-05-18 EP EP22204799.5A patent/EP4186518A1/en not_active Withdrawn
-
2018
- 2018-10-21 IL IL262501A patent/IL262501A/en unknown
- 2018-11-05 MX MX2022008602A patent/MX2022008602A/es unknown
- 2018-11-15 US US16/192,274 patent/US10646549B2/en active Active
-
2020
- 2020-04-07 US US16/842,300 patent/US11000573B2/en active Active
-
2021
- 2021-05-05 US US17/308,686 patent/US11311602B2/en active Active
-
2022
- 2022-04-15 US US17/721,583 patent/US11571463B2/en active Active
-
2023
- 2023-02-06 US US18/164,796 patent/US20240024422A1/en active Pending
- 2023-03-15 JP JP2023040409A patent/JP2023072056A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3458083T3 (da) | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf | |
DK3679715T3 (da) | Kodningsfremgangsmåde og - anordning | |
DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
DK3481948T3 (da) | Xylanasevarianter og polynukleotider, der koder for dem | |
DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
DK3118096T3 (da) | Cykelstel, energiforsyningsenhed hertil og elcykel hermed | |
DK3720955T3 (da) | Alfa-amylasevarianter og polynukleotider, der koder for dem | |
DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
DK2980328T3 (da) | Nedsivningsblokelement, nedsivningsblok og transportenhed | |
DK3362574T3 (da) | Glucoamylasevarianter og polynukleotider, der koder for dem | |
DK3640207T3 (da) | Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf | |
DK3487996T5 (da) | Serinproteasevarianter og polynukleotider, der koder for samme | |
DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
DK3359773T3 (da) | Datasystemer, anordninger og fremgangsmåder | |
DK3420039T3 (da) | Printningsformuleringer og fremgangsmåder | |
DK3516160T3 (da) | Brøndanordning og tilhørende fremgangsmåder | |
DK3464338T3 (da) | Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed | |
DK3720956T5 (da) | Alfa-amylasevarianter og polynukleotider, der koder for dem | |
DK3353191T3 (da) | Cykliske polypeptider, fremgangsmåde til opnåelse deraf og terapeutisk anvendelse deraf | |
DK3429977T3 (da) | Gipsplade, fremgangsmåde til fremstilling og anvendelse heraf | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
DK3526443T3 (da) | Borehulsanordninger, tilhørende anordning og fremgangsmåder | |
DK3537803T3 (da) | Basisstation, brugerudstyr og relaterede fremgangsmåder | |
DK3263188T3 (da) | Trampolinsystemer og fremgangsmåder til fremstilling og anvendelse deraf | |
DK3458707T3 (da) | Energiudbytteanordning, der omdanner fleraksial translationel og roterende bevægelse til ensrettet roterende bevægelse |